Live Breaking News & Updates on Clara Campal Hospital

Stay updated with breaking news from Clara campal hospital. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Alkermes plc: Alkermes Presents New Nemvaleukin Alfa Monotherapy Data at the American Society of Clinical Oncology Genitourinary Cancers Symposium

- Data From ARTISTRY-1 Clinical Trial Highlight Single-Agent, Anti-Tumor Activity of Nemvaleukin in Patients With Renal Cell Carcinoma - DUBLIN, Feb. 17, 2022 /PRNewswire/ Alkermes ....

United States , Emiliano Calvo , Craig Hopkinson , Sandy Coombs , Sourojit Bhowmick , American Society Of Clinical Oncology , Research Development At Alkermes , Merck Sharp Dohme Corp , Exchange Commission , Nemvaleukin Clinical Development Program , Merck Co Inc , Clinical Research , Trial Highlight Single Agent , Anti Tumor Activity , Patients With Renal Cell Carcinoma , American Society , Clinical Oncology , Cancers Symposium , Chief Medical Officer , Executive Vice President , Nemvaleukin Alfa , Patients With Advanced Renal Cell Carcinoma , Medical Oncologist , Centro Integral Oncol , Clara Campal Hospital , Nemvaleukin Clinical Development ,

Alkermes Presents New Nemvaleukin Alfa Monotherapy Data at the American Society of Clinical Oncology Genitourinary Cancers Symposium

/PRNewswire/ Alkermes plc (Nasdaq: ALKS) today presented new data from the ongoing phase 1/2 ARTISTRY-1 clinical trial for nemvaleukin alfa (nemvaleukin),. ....

United States , Emiliano Calvo , Craig Hopkinson , Sandy Coombs , Sourojit Bhowmick , American Society Of Clinical Oncology , Research Development At Alkermes , Merck Sharp Dohme Corp , Exchange Commission , Nemvaleukin Clinical Development Program , Merck Co Inc , Clinical Research , American Society , Clinical Oncology , Cancers Symposium , Chief Medical Officer , Executive Vice President , Nemvaleukin Alfa , Patients With Advanced Renal Cell Carcinoma , Medical Oncologist , Centro Integral Oncol , Clara Campal Hospital , Nemvaleukin Clinical Development , Private Securities Litigation Reform Act , Annual Report , Merck Sharp ,